TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* be ≥ 18 years old,~* have a diagnosis of diabetes and hypertension,~* be prescribed 3 or more drugs to treat these conditions,~* speak English or Spanish as their primary language,~* have primary responsibility for administering their own medications,~* be a registered UNC patient.~Exclusion Criteria:~* severe, uncorrectable visual, hearing or cognitive impairments that would preclude study consent or participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Adult patients with diabetes and hypertension (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Withdrawal of Steroids, Cyclosporine A Dose Reduction and Switch to Mycophenolatmofetile After Heart Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Current immunosuppressive regimen: Cyclosporine A and corticosteroids for at least six month~* Heart transplantation above 3 years dated back~* Serum creatinine \< 3,5 mg/dl (310 µmol/l) and BUN \< 150 mg/dl~* Cyclosporine A blood level between 50 and 250 ng/ml during the last 12 month~Exclusion Criteria:~* Carcinoma within the last 3 years~* Acute rejection episodes during the last 6 month~* Infection requiring therapeutic intervention~* Hepatitis B, Hepatitis C or HIV infection~* WBC \< 3000/µl, haemoglobin \< 9g/dl, platelets \< 70.000/µl~* Florid gastrointestinal ulcer~* Haemodialysis within the last 4 weeks before study entry~* Pregnancy / lactation~* Administration of other immunosuppressive agents than prescribed~* Mycophenolatmofetile incompatibility

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal; Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily; Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 mg/ml

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients with multiple myeloma receiving an autologous HCT are eligible when the following criteria are met:~1. 18-75 years of age~2. ≤ 1 year since initiation of systemic anti-myeloma therapy~3. Patient is scheduled for autologous hematopoietic stem cell transplant as the upfront therapy for their multiple myeloma~4. Karnofsky Performance Status of ≥90 %; patients eligible for HCT are eligible for the study~5. All men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertile.~Exclusion Criteria:~1. Prior autologous HCT~2. Non secretory multiple myeloma~3. Concurrent beta-blocker therapy at or within 3 weeks of study entry.~4. Previous intolerance to beta-blocker therapy~5. Any medical contraindications to beta-blocker therapy including, but not limited to, symptomatic hypotension; drug hypersensitivity; sinus bradycardia, sick sinus syndrome, or 2nd or 3rd degree atrioventricular block without a pacemaker; uncompensated heart failure; or uncontrolled asthma~6. Active, untreated depression screened for by the HCT physician (Patients who screen positive will be offered a referral to the Medical College of Wisconsin Psycho-Oncology program for further evaluation and treatment)~7. Concurrent use of medications as specified in the protocol throughout the study or within one week of study entry.~8. Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Propranolol (Type: EXPERIMENTAL): Patient's randomized to the Propranolol arm will be starting 7 days prior to transplant and continuing through 28 days post-transplant. Propranolol will start at 20mg twice daily and will be titrated to 40mg twice daily as tolerated. Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for up to 7 total weeks for patient's on the Propranolol arm.
- Control Arm (Type: NO_INTERVENTION): Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for 6 total weeks for patient's on the control arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 18 - 70~* History of intractable localization related/partial onset seizures and generalized tonic/clonic or tonic seizures defined according to International League Against Epilepsy (ILAE) classification as:~* A history compatible with localization related partial epilepsy~* A history of generalized tonic clonic or tonic seizures with loss of consciousness~* Three or more simple partial, complex partial or tonic-clonic seizures per month~* An EEG and/or an MRI consistent with a localization related epilepsy~* Evidence of at least three seizures per month for at least two months prior to the study~* Exposure to at least one antiepileptic drug at adequate dose~Exclusion Criteria:~* Significant or progressive medical, cardiac, or other illness~* Allergy to fish products or fish oil~* History of a coagulation disorder~* History of non-epileptic seizures~* Consumption of Fish Oil at any time 30 days or less prior to enrollment~* Any change in antiepileptic drugs for 30 days or less prior to enrollment~* Treatment with Warfarin for 30 days or less prior to enrollment~* Previous poor compliance with therapy~* Drug or alcohol abuse~* Uncountable seizures as a result of seizure clustering, or inadequate supervision if the patient cannot count their own seizures.~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Corn Oil Placebo (n-6 fatty acids)
- High Dose Fish Oil (Type: EXPERIMENTAL): 2160 mg of EPA + DHA
- Low Dose Fish Oil (Type: EXPERIMENTAL): 1060 mg of EPA + DHA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. The body mass index is 18-28kg/m2 (including the critical value), which allows the minimum weight of men to be 50kg (including the critical value) and 45kg for women (including the critical value).~2. Before the study,participant has know about the significance , potential benefits, inconveniences and potential risks of the study~3. Participant has understood the research's procedure and sign the informed consent .~Exclusion Criteria:~* Participant who are Pregnancy, lactating women, and planned trials begin within six months of pregnancy~* Participant who has abnormal Physical examination, laboratory examination results and clinical significance (such as: liver function examination - aspartate aminotransferase (AST) and alanine aminotransferase (ALT) more than 1.5 times that of the upper limit of normal)~* Participant who has a history of cardiovascular, liver, kidney, digestive tract, nervous system, blood system, familial hematologic disease, abnormal thyroid function, or mental abnormality~* Participant who has drug allergy history and anaphylactic reaction~* Participant who took oral contraceptive in 6 months~* Participant who used any drug (including Chinese herbal medicine) within 1 week.~* Participant who donated blood within 2 months~* Participant who participated clinical trials of any drug in 3 months (as subjects)~* Participant who has any positive result of virus serology check: human immunodeficiency virus antigen antibody (HIV Ag/Ab) and hepatitis c virus (HCV) - immunoglobulin G(IgG) antibody to IgG, hepatitis b surface antigen (HBsAg) and treponema pallidum antibody (TP)~* Participant who are used to smoke, alcohol abuse, eat coffee and strong tea and drug abuse~* Participant who the researchers believe that there are volunteers who are not suitable for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- SPH3127 100mg (Type: EXPERIMENTAL): A single dose of SPH3127 50 mg\*2 qd \*7 days
- Placebo to SPH3127 100mg (Type: PLACEBO_COMPARATOR): A single dose of placebo matching to SPH3127 50mg\*2 qd \*7 days
- SPH3127 200mg (Type: EXPERIMENTAL): A single dose of SPH3127 100 mg\*2 qd \*7 days
- Placebo to SPH3127 200mg (Type: PLACEBO_COMPARATOR): A single dose of placebo matching to SPH3127 100mg\*2 qd \*7 days
- SPH3127 400mg (Type: EXPERIMENTAL): A single dose of SPH3127 100 mg\*4 qd \*7 days
- Placebo to SPH3127 400mg (Type: PLACEBO_COMPARATOR): A single dose of placebo matching to SPH3127 100mg\*4 qd \*7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Analgesic Effect of Midazolam and Ketamine as an Additive to Intrathecal Bupivacaine in Patients Undergoing Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients with American Society of Anesthesiologists(ASA) physical status I and II, undergoing elective cesarean section~Exclusion Criteria:~* significant coexisting disease such as hepato-renal and cardiovascular disease~* any contraindication to regional anesthesia such as local infection or bleeding disorders~* allergy to ketamine or midazolam~* long-term opioid use or a history of chronic pain.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: ACTIVE_COMPARATOR): The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally .
- midazolam (Type: ACTIVE_COMPARATOR): The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
- placebo (Type: PLACEBO_COMPARATOR): The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Lidocaine Administration in Thoracoscopic Surgery for Improved Postoperative Pain Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing video-assisted thoracoscopic procedures under general anaesthesia.~* American Society of Anesthesiologists (ASA) physical Status classes I to III~* age ≥ 18 years~* Patient informed consent~Exclusion Criteria:~* Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product~* Contraindications to self-administration of opioids~* Women who are pregnant or breast feeding~* Steroid therapy~* Chronic pain therapy~* Atrioventricular block grade II to III~* Congestive heart failure~* Liver insufficiency~* Known or suspected non-compliance, drug or alcohol abuse~* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia~* Participation in another study with investigational drug within the 30 days preceding and during the present study,~* Enrolment of the investigator, his/her family members, employees and other dependent persons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): perioperative IV administration regimen of lidocaine will be as follows: 1.5 mg/kg IV induction bolus dose (before intubation and at least 30 minutes before incision) followed by continuous infusion of 3.mg/kg/h, until 2 hours after skin closure
- Placebo (Type: PLACEBO_COMPARATOR): perioperative IV administration regimen of placebo solution (NaCl 0,9%) will be as follows: induction bolus (before intubation and at least 30 minutes before incision) followed by continuous infusion of placebo solution (NaCl 0,9%) until 2 hours after skin closure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants or children (newborn to 17 years of age) undergoing cardiopulmonary bypass for elective surgical correction of a congenital heart defect.~* Patients must be taking an ACE inhibitor prior to their operation~Exclusion Criteria:~* Patients in which discontinuing ACEIs is deemed unsafe by their primary cardiologist~* Any condition rendering the subjects legal guardian unable to understand the nature, scope, and possible consequences of the study.~* Pregnancy as ruled out by standard of care screening procedures.~* Individuals whose weight is less than 3.5 kg at the time of enrollment.~* Inability to comply with the protocol. ie. Children in whom it is deemed unsafe to have the extra blood draws, and children who are thought to be noncompliant with their medications.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- ACE inhibitor (Type: EXPERIMENTAL): Patients already on an ACE inhibitor will continue it until the day of surgery
- No ACE inhibitor (Type: EXPERIMENTAL): Patients on ACE inhibitors who are randomized to stop their ACE inhibitor 48 hours prior to surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of rheumatoid arthritis based on 2010 ACR/EULAR criteria for at least 4 months.~At least 6 tender (of 68 assessed) and 6 swollen (of 66 assessed) joints at screening and baseline.~HS-CRP equal or greater than 10 mg/L.~Must have received methotrexate for at least 12 weeks and be on a stable dose for at least 4 weeks.~Exclusion Criteria:~Evidence of untreated or inadequately treated latent or active TB.~Evidence or history of moderate or severe heart failure (NYHA Class III/IV)~Infection requiring hospitalization or parenteral antimicrobial therapy judged clinically significant by the investigator within 6 months prior to first dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-06438179 (Type: EXPERIMENTAL): None
- Infliximab (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Effect of Itraconazole on the PK of Multiple Doses of Balovaptan in Healthy Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female subjects. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, urinalysis, and serology.~* Body Mass Index of 18 to 30 kg/m2, inclusive.~* For women of childbearing potential: agreement to use at least 2 acceptable contraceptive methods during the treatment period and for 90 days after the last dose of study drug.~* For men: agreement to use contraceptive measures, and agreement to refrain from donating sperm until 90 days after the last dose of study drug.~Exclusion Criteria:~* Female subjects who are pregnant or lactating.~* Any condition or disease detected during the medical interview/physical examination that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Balovaptan + Itraconzole (Type: EXPERIMENTAL): Dosing in Period 1 was separated by at least a 7 day washout period before dosing starts in Period 2. Participants received the study drugs in 2 periods over a total of 37 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations~Exclusion Criteria:~* Any significant acute or chronic medical illness or relevant trauma (e.g., history of chronic hypertension, bacterial endocarditis, hemorrhagic stroke, motor vehicle accident resulting in significant head trauma or internal injuries)~* History or evidence of abnormal bleeding or coagulation disorder (e.g., easy bruising or gingival bleeding, prolonged bleeding after dental extraction, postpartum, or after trauma, wounds or surgery)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A: Apixaban tablet (Type: EXPERIMENTAL): Apixaban Film coated Tablet Single dose 10 mg orally
- Treatment B: Apixaban oral solution (Type: EXPERIMENTAL): Apixaban Solution Single dose 10 mg orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Post-Authorisation Study on the Use of Bemfola® in Human Assisted Reproductive Techniques in Spain.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women aged ≥ 18 years~* Currently undergoing an IVF or ICSI cycle or are oocyte-donors~* Have completed controlled ovarian stimulation~* Have received at least 5 doses of Bemfola®~* Are pituitary suppressed with a GnRH antagonist~* Have undergone oocyte retrieval~* Have signed the Informed Consent Form~Exclusion Criteria:~* Hypersensitivity to the active substance follitropin alfa, FSH or to any of the excipients listed~* Presence of tumours of the hypothalamus or pituitary gland

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Minimally Invasive Restorative Techniques on Pregnant Women Oral Health Related Quality of Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Having at least one carious lesion involving dentine with lesion accessible to hand instruments (International Caries Detection and Assessment System score= 5 or 6).~* Suffering from at least mild dental pain as identified by a score of at least 5mm on a Visual Analogue Scale (VAS) 100-mm-long.~Exclusion Criteria:~* Pregnant women with acute pulpitis, swelling or fistula.~* Uncooperative patients and those who refused to participate.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Papacarie-Duo (Type: EXPERIMENTAL): None
- Atraumatic Restorative Treatment (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete